The POLARIS training network
POLARIS is a European Marie Skłodowska-Curie Doctoral Network focused on accelerating therapy development for leukodystrophies: rare genetic disorders affecting the brain white matter. The network aims to strengthen the full translational pathway from disease mechanism and model development to preclinical therapy testing, clinical readiness and patient-informed treatment priorities.
To achieve this, POLARIS brings together expertise in leukodystrophy biology, advanced disease models, therapeutic innovation, biomarker development, clinical translation, patient engagement, and ethical, regulatory and health-economic aspects of therapy development. The network will train a cohort of doctoral candidates in an international and interdisciplinary environment, combining academic research, industry-based preclinical development, secondments, network-wide training and transferable-skills development.
The PhD
For this position, the recruiting organisation is InnoSer in Leiden, the Netherlands. You will be employed by InnoSer and embedded in the POLARIS consortium, with academic supervision and disease-specific expertise provided by Dr Rogier Min at the Amsterdam Leukodystrophy Center (ALC), Amsterdam UMC.
The position is primarily based at InnoSer in Leiden, with regular academic interaction with the Amsterdam Leukodystrophy Center in Amsterdam. This includes approximately one day per week at Amsterdam UMC.
The academic embedding will be at the Amsterdam Leukodystrophy Center, with the anticipated PhD defence at the Faculty of Medicine, Vrije Universiteit Amsterdam.
This PhD project focuses on characterising leukodystrophy mouse models and evaluating promising proof-of-concept interventions. You will conduct longitudinal studies in mouse models, with a particular focus on megalencephalic leukoencephalopathy with subcortical cysts (MLC).
The project combines behavioural and neurological phenotyping with the development of an automated EEG analysis pipeline. You will use these approaches to define robust disease phenotypes, assess disease progression and identify EEG biomarkers that can support future preclinical therapy studies.
You will also test selected candidate therapies emerging from other POLARIS work packages. By aligning preclinical readouts with clinically relevant endpoints, your work will contribute to the translational value of leukodystrophy models.
You will work at the interface of preclinical research, academic leukodystrophy expertise and patient-oriented therapy development. Your work will include:
Planned secondments will broaden your expertise through hands-on training in lipid nanoparticle delivery. You will also have opportunities to engage with patients and families to better understand leukodystrophies and the priorities of affected communities.
We are looking for a motivated researcher with an interest in translational neuroscience, rare diseases and preclinical therapy development. You bring:
Experience with animal welfare principles, robust experimental design and formal certification for working with laboratory animals, such as FELASA or an equivalent qualification, is an advantage.
Because the project includes EEG analysis and the development of an automated analysis pipeline, experience with scripting and data analysis, for example in R or Python, is also an advantage. You do not need to have experience in all these areas: if you are motivated to develop these skills, we encourage you to apply.
You work accurately and reproducibly, pay attention to detail and can plan and organise complex experimental work. You will work with colleagues at InnoSer, Amsterdam UMC and other POLARIS partner organisations and should be comfortable working in an interdisciplinary and international setting.
Fluency in written and spoken English is essential.
Eligibility criteria
Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:
A contract for 12 months, with the intention to extend for a total of 3 years;
Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules;
Embedding in the international POLARIS doctoral training network;
Access to network-wide training activities, secondments and transferable-skills development;
A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical therapy development;
A collaborative and entrepreneurial working environment;
An open and supportive team culture with opportunities for scientific and professional development.
Non-EU/EEA/Swiss applicants require a valid residence permit to live and work in the Netherlands.
You will work at InnoSer in Leiden, a European preclinical contract research organisation (CRO) that supports biotechnology and pharmaceutical partners with tailored in vitro and in vivo research services. InnoSer works with clients from study design through execution and data analysis and has facilities in Belgium and the Netherlands.
At the Leiden facility, research focuses on rare genetic diseases affecting the nervous system and neurodegenerative diseases, using in vivo mouse models. You will work in a research environment where preclinical studies contribute directly to decisions about the development of potential therapies.
You will also be closely connected to the Amsterdam Leukodystrophy Center at Amsterdam UMC. The ALC combines specialist clinical care, diagnostics, patient-oriented research and translational neuroscience. Dr Rogier Min’s team studies astrocyte and white matter biology in leukodystrophies, with a particular focus on ion, water and volume regulation. The team combines patient genetics with mouse models, cell culture, electrophysiology and advanced imaging.
You will also be part of the international POLARIS doctoral network. You will work with researchers from different scientific disciplines and collaborate with academic and industry partners across Europe. Through secondments, network-wide training and transferable-skills development, you will build experience beyond your own research project and develop an international research network.
POLARIS is committed to open, transparent and merit-based recruitment. We value diversity and welcome candidates with different backgrounds, perspectives and experiences.
The application deadline is 5 October 2026. We aim to select the final candidate in October/November 2026.
Applicants may, where appropriate and in line with the recruitment procedure, also be considered for other POLARIS doctoral candidate positions that better match their profile and interests. You can highlight up to two additional POLARIS projects of interest in your application letter. This does not replace your application to the primary position, but helps the consortium identify potential alternative matches where relevant.
Would you like to know more about this PhD position? For substantive information about the vacancy, please contact dr Maarten Loos, via mloos@innoserlaboratories.com.
Acquisition in response to this vacancy will not be considered.


